^
Association details:
| Biomarker: | CD20 positive |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) + Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
07/28/2023
Excerpt:
Acute Lymphoblastic Leukemia: PRINCIPLES OF SYSTEMIC THERAPY FRONTLINE REGIMENS FOR B-ALL...Other recommended regimens...Hyper-CVAD...± blinatumomab with rituximab for CD20-positive disease...
Secondary therapy:
CVAD
